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HREV107 type II tumor suppressorRetinoid-inducible gene 1 (RIG1), also called tazarotene-induced gene 3, belongs to the HREV107 gene fam-
ily, which contains ﬁve members in humans. RIG1 is expressed in high levels in well-differentiated tissues,
but its expression is decreased in cancer tissues and cancer cell lines. We found RIG1 to be highly expressed
in testicular cells. When RIG1 was expressed in NT2/D1 testicular cancer cells, neither cell death nor cell vi-
ability was affected. However, RIG1 signiﬁcantly inhibited cell migration and invasion in NT2/D1 cells. We
found that prostaglandin D2 synthase (PTGDS) interacted with RIG1 using yeast two-hybrid screens. Further,
we found PTGDS to be co-localized with RIG1 in NT2/D1 testis cells. In RIG1-expressing cells, elevated levels
of prostaglandin D2 (PGD2), cAMP, and SRY-related high-mobility group box 9 (SOX9) were observed. This
indicated that RIG1 can enhance PTGDS activity. Silencing of PTGDS expression signiﬁcantly decreased
RIG1-mediated cAMP and PGD2 production. Furthermore, silencing of PTGDS or SOX9 alleviated
RIG1-mediated suppression of migration and invasion. These results suggest that RIG1 will suppress cell
migration/invasion through the PGD2 signaling pathway. In conclusion, RIG1 can interact with PTGDS to en-
hance its function and to further suppress NT2/D1 cell migration and invasion. Our study suggests that
RIG1-PGD2 signaling might play an important role in cancer cell suppression in the testis.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Retinoid-inducible gene 1 (RIG1), also called tazarotene-induced
gene 3 (TIG3) or retinoic acid receptor responder 3 (RARRES3) [1–3],
is an HREV107 type II tumor suppressor and thereby belongs to the
Nlpc/p60 superfamily and the LRAT (Lecithin:retinol acyltransferase)-
like family [4,5]. Proteins of this family contain a proline-rich motif
located at the N-terminus, followed by a conserved H-box, the NC
domain, and a C-terminal transmembrane domain [4,5].
HREV107, RIG1, and HRASLS are involved in the regulation of
cellular growth, apoptosis, and differentiation [6–13]. The genes are
expressed in normal tissues in a tissue-speciﬁc manner, and they
are down-regulated in various cancer tissues [14–17]. HREV107 is
expressed at high levels in differentiated tissues of post-meiotic tes-
ticular germ cells but not human testicular germ cell tumors [15].ddhist Tzu Chi General Hospital
i City 231, Taiwan. Tel.: +886 2
rights reserved.Also, terminal differentiation accompanied by the induction of cellu-
lar apoptosis and inhibition of cell growth has been observed in
keratinocytes after induced RIG1 expression [12,13]. Therefore, the
HREV107 protein family appears to play an active role in the regula-
tion of cellular differentiation in both normal and cancer cells.
Cumulative evidence suggests a possible mechanism through
which the HREV107 protein family affects cell differentiation and
the suppression of cancer progression. Several studies have observed
anti-RAS and phospholipid-metabolizing activities among these
proteins. Murine H-rev 107 was ﬁrst isolated from revertants of
HRAS-transformed ﬁbroblasts [6]. Subsequently, RIG1, HREV107,
and HRASLS were shown to inhibit RAS-mediated signaling of ﬁbro-
blasts or cancer cell lines [8,10,11,18,19]. Our study further demon-
strated a down-regulation caused by RIG1 of activated RAS and total
RAS protein, via a posttranslational mechanism [10,11]. Aside from
its role in inhibiting RAS activity, the HREV107 protein family could
be a phospholipid-metabolizing enzyme. HREV107 catalyzes the efﬁ-
cient release of free fatty acids and lysophospholipid from phosphati-
dylcholine, indicating that it is a phospholipase A1/A2 [20]. Also,
different members of the HREV107 family can react with various
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sults suggest that the tumor suppressors RIG1, HRASLS2, and
HREV107 are involved in phospholipid metabolism with different
physiological roles.
Prostaglandins (PGs) are lipid-derived autacoids generated by se-
quential metabolism of arachidonic acid by the cyclooxygenase (COX)
and prostaglandin synthase enzymes. Arachidonic acid is a 20-carbon
unsaturated fatty acid that esteriﬁes to the sn-2 position of membrane
glycerophospholipids. When arachidonic acid is released from the
membrane by phospholipase A2, it undergoes oxidation by cyclooxy-
genase (prostaglandin endoperoxide H synthase, PGHS) to PGG2
followed by reduction to the unstable endoperoxide PGH2 [22]. This in-
termediate is then switched by different enzymes in the prostanoid
biosynthetic pathway. These enzymes are named according to the
prostanoid that they produce, such that prostaglandin D2 (PGD2) is
synthesized by prostaglandin D synthase (PTGDS), PGF2a by PGFS,
PGI2 by PGIS, thromboxane (TXA2) by thromboxane synthase (TXS),
and PGE2 by PGES [23]. PGD2 is synthesized in many organs and has
been implicated as a signaling molecule in the mediation or the regula-
tion of various biological processes. Previous studies have shown that
the ptgds gene is male speciﬁcally expressed in early stages of mouse
gonadogenesis [24]. Furthermore, PGD2 has an effect at the posttrans-
lational level on nuclear translocation of the SRY-related high-mobility
group box 9 (SOX9) protein by the cAMP/PKA pathway, subsequently
inducing Sertoli cell differentiation [25].
RIG1 stimulates cellular differentiation of keratinocytes, which is
mediated by the activation of type I tissue transglutaminase [12,13].
In addition, RIG1 was shown to inhibit RAS signal pathways in cervi-
cal and gastric cancer cells [10]. However, the direct interactions of
RIG1/Type I tissue transglutaminase or RIG1/RAS were not observed
in testicular and cervical cancer cells. Although the HREV107 protein
family exhibits activities that can regulate cellular differentiation and
suppress cancer cells, the exact mechanism has not been determined.
We performed yeast two-hybrid screening and by using the function-
al NC domain of RIG1 [26] as bait, found that RIG1 can interact with
PTGDS. In this study, we showed that RIG1 can suppress cancer cell
migration/invasion by interacting with PTGDS and inducing its activ-
ity in testicular cell lines. We further dissected the molecular mecha-
nism through which PGD2 suppresses cancer cell migration and
invasion. Our results suggest that the invasion and migration abilities
of cancer cells are controlled by the expression and interaction of
RIG1 and PTGDS.
2. Methods
2.1. Materials
All the chemicals were purchased from Sigma-Aldrich except
PGD2, BWA868C, BAY-u3405, and arachidonyl triﬂuoromethyl ketone
(AACOCF3) (Cayman Chemical, Ann Arbor, MI).
2.2. Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA from human tissue was obtained from Clontech (BD
Biosciences, Palo Alto, CA). Ten testis RNA samples derived from
four normal testes, carcinoma of three testes, and seminoma of
three testes were purchased from Origene Technologies (Rockville,
MD). cDNA was prepared using M-MLV reverse transcriptase
(Invitrogen, Carlsbad, CA) and oligo (dT)12–18. Conventional RT-PCR
was used to analyze levels of RIG1 and PTGDS expression in human
tissues. The PCR reaction was conducted in a 25-μL reaction mixture
containing 1 μL of cDNA, 10 mM Tris–HCl (pH 9.0), 50 mM KCl,
0.01% (w=v) gelatin, 0.1% Triton X-100, 2 mM MgCl2, 20 mM
dNTP, 100 nM primers for RIG1, PTGDS, or actin, and 1 unit of
Pro-Taq DNA polymerase (Protech Technology Enterprise Co., Taipei,
Taiwan). The reaction mixtures were subjected to initial 95 °Cincubation for 2 min and then ampliﬁed for 25 to 35 cycles (94 °C
for 30 s, 61 °C for 60 s, and 72 °C for 60 s) in a GeneAmp® PCR Sys-
tem 9700 Thermal Cycler (Applied-Biosystems, Foster City, CA). Five
microliters of the ampliﬁed product was analyzed by electrophoresis
on 2% agarose gel, and images were recorded using the Gel Logic 100
Imaging System (Kodak). Primers used for ampliﬁcation of RIG1
(5′-AAGTGAGTACCCCGGGGCTGG-3′ and 5′-ACGGGCCGTGGTTGGTA
CTC-3′), PTGDS (5′-CCGTGCAGCCCAACTTCCAG-3′ and 5′-GCAGCATG
GTTCGGGTCTCAC-3′), and actin (5′-TCCCTGGAGAAGAGCTACG-3′
and 5′-GTAGTTTCGTGGATGCCACA-3′) are indicated.
Quantitative real-time PCR was performed in triplicate in 20 μL of
a reaction mixture containing 10 μL Fast SYBR Green Master Mix
(Applied-Biosystems), 50 ng cDNA, and 100 nM of each primer in a
thermal cycler (7900HT Fast Real-Time PCR System, ABI). The PCR cy-
cling comprised an initial incubation at 95 °C for 3 min, 40 cycles of
denaturation at 95 °C for 15 s, and annealing and extension at 60 °C
for 1 min. Expression data were normalized on the mean of actin
gene expression data.2.3. Expression vectors
The vectors pRIG1-myc, pRIG1ΔC-myc, pDsRed-RIG1, and pDsRed-
RIG1ΔC have been described previously [10,26]. To generate
pPTGDS-Flag, the PTGDS cDNA fragment was ampliﬁed from pPTGDS/
PACT2 using 5′ (5′-TGGCTAGCATGGCTACTCATCACACGCTGTG-3′) and
3′ (5′-CGGAATTCGTTGTTCCGTCATGCACTTATCG-3′) primers, and then
subcloned in-frame into NheI-EcoRI of PCR3.1-Flag. To generate
pEGFP-PTGDS, the PTGDS cDNA fragment was ampliﬁed from the
pPTGDS-Flag using 5′ (5′-TCGAATTCTATGGCTACTCATCACACGCTGTG-
3′) and 3′ (5′-GTGGATCCTTGTTCCGTCATGCACTTATCG-3′) primers,
and then subcloned in-frame into EcoRI-BamHI sites of the pEGFP-C1
vector (Clontech Laboratories Inc., Palo Alto, CA). The cDNA sequences
of fusion proteins were conﬁrmed by DNA sequencing.2.4. Cell culture and transfection
NT2/D1 testicular cancer cells were maintained in Dulbecco's Mod-
iﬁed Essential Medium (DMEM) supplemented with 25 mM HEPES,
26 mMNaHCO3, 2 mM L-glutamine, penicillin (100 units/mL), strepto-
mycin (100 μg/mL), and 10% fetal bovine serum (FBS) at 37 °C in 5%
CO2. Cells plated in culture dishes were transfected with the expression
vectors using liposome mediated-transfection. Brieﬂy, plasmids and
lipofectamine 2000 (Gibco BRL, Gaithersburg, MD) were diluted in
Opti-MEM medium and then mixed with plasmids at room tempera-
ture for 15 min. The DNA–lipofectamine complexes were then added
to cells for 5 h at 37 °C. Cells were refreshed with complete medium
for 24 h at 37 °C for further analysis.2.5. Analysis of cell death and viability
Cells were plated in triplicate in 24-well plates at a density of 2×104
cells perwell inDMEMmedium containing10% FBS andwere incubated
overnight. The cells were transfected with 500 ng of RIG1, RIG1ΔC ex-
pression vectors, or empty control vector and then refreshedwith com-
plete medium immediately and 24 h after transfection. Cells were
analyzed for viability using the WST-1 reagent (100 μL Roche Diagnos-
tics, Mannheim, Germany). Cell viability relative to that of control
transfected cells was deﬁned as [(A450–A660) of RIG1-transfected
cells/(A450–A660) of control transfected cells]×100%. Measurement
of the release of lactate dehydrogenase (LDH)using theCytotoxicity De-
tection Kit (Roche) was used to evaluate cell death as described previ-
ously [26]. Percentage LDH release was deﬁned as [(A490–A650) of
RIG1-cells/(A490–A650) of control transfected cells]×100%.
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For cell migration assay, 2×104 NT2/D1 cells were added to the
upper polycarbonate membrane insert (8 μm pore size; Falcon,
Becton Dickinson) of the cell migration assay kit in a 24-well
plate. In the lower well, 700 μL DMEM with 20% FBS was used as
chemoattractant. After 24 h of incubation, cells were methanol
ﬁxed for 10 min at room temperature and then stained for
30 min at room temperature with a 50 μg/mL solution of
propidium iodide (Sigma-Aldrich). Polycarbonate-membrane in-
serts coated with 30 μg Matrigel (BD) were used for cell invasion
assays. NT2/D1 cells were suspended in DMEM medium containing
10% NuSerum (Invitrogen). 2×104 cells were placed in the upper
chambers, and 700 μL of medium was placed in the lower cham-
bers. After incubation for 72 h at 37 °C, cells were ﬁxed and
stained for propidium iodide. The number of cells on each mem-
brane was counted under a microscope at a magniﬁcation of 40×.
Experiments were performed at least twice, and each sample was
assayed in triplicate.
2.7. Immunoprecipitation, nuclear and cytoplasmic fractionation, and
Western blotting
Cells were lysed in IP lysis buffer (20 mM Tris–HCl at pH 7.5,
100 mM NaCl, 1% Nonidet P40, 100 μM Na3VO4, 50 mM NaF,
30 mM sodium pyrophosphate) containing 1× complete protease
inhibitor cocktail (EDTA-free) (Roche). Cell lysates containing
500 μg of protein were incubated ﬁrst with 3.2 μg of anti-myc
(Invitrogen) or 1 μg of anti-Flag-M2 (Sigma-Aldrich) monoclonal
antibody for 2 h at 4 °C, and then incubated with 20 μL of protein
G plus/protein A agarose (Calbiochem, Cambridge, MA) at 4 °C for
2 h. Immunoprecipitated complexes were washed three times
with IP lysis buffer and then analyzed by Western blotting using
an anti-myc or anti-Flag antibody. Alternatively, cell lysates
containing 5 mg of protein were incubated ﬁrst with 4 μg of normal
rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA), 4 μg of
anti-RIG1 (Santa Cruz Biotechnology), or 4 μg of anti-PTGDS
(Santa Cruz Biotechnology) antibody for 12 h at 4 °C and then incu-
bated with 20 μL of protein G plus/protein A agarose (Calbiochem)
at 4 °C for 2 h. Immunoprecipitated complexes were washed three
times with IP lysis buffer and then analyzed by Western blotting
using anti-RIG1 (Santa Cruz Biotechnology) or anti-PTGDS (Abcam,
Cambridge, UK) antibody. To determine the nuclear or cytosolic dis-
tribution of SOX9, cell fractionation was performed using the
Qproteome cell compartment kit (Qiagen, Valencia, CA) according
to the manufacturer's instructions with the addition of protease
and phosphatase inhibitors to all buffers. For Western blotting, pro-
teins (20–50 μg) were separated on 12% polyacrylamide gels and
transferred to polyvinylidene diﬂuoride membranes. After blocking,
membranes were incubated with anti-myc, anti-Flag, anti-PTGDS
(Abcam), anti-phospho-SOX9 (Abcam), anti-SOX9 (Abcam), anti-
lamin B1 (Invitrogen), anti-glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) (Cell Signaling Technology, Beverly, MA), or
anti-actin (Sigma-Aldrich) antibody for 12 h at 4 °C, and then incu-
bated with horseradish peroxidase-conjugated goat anti-mouse an-
tibody at room temperature for 1 h. An ECL kit (Amersham, Bucks,
UK) was used to detect the substrate reaction.
2.8. Confocal and immunoﬂuorescent analysis
NT2/D1cells (1×105) were plated on poly-L-lysine-coated cover-
slips in 35-mm dishes in growth medium. Cells were then transfected
with 500 ng of DsRed-RIG1 or pDsRed-RIG1ΔC with 500 ng pEGFP-
PTGDS expression vector for 18 h. The cells were washed and ﬁxed
with 4% paraformaldehyde and then analyzed with a Leica TCS SP5
scanner (Leica, Bensheim, Germany).2.9. Measurement of PGD2 and cAMP levels
Cells were cultured onto 6-well plates overnight and then
transfected with 500 ng pPTGDS-Flag along with 500 ng of pRIG1-
myc, pRIG1ΔC-myc, or control vector in complete medium for 24 h
or treated with PGD2 (500 ng/mL) for 30 min, 1 mM Br-cAMP for
18 h. After washing twice with PBS, cells were lysed with 0.1 N HCl
for 20 min, scraped, and collected by centrifugation. Levels of PGD2
or cAMP in the supernatants were determined using a prostaglandin
D2 express or cyclic AMP EIA kit (Cayman Chemical) according to
the manufacturer's instructions.
2.10. Viruses and transduction
LacZ, PTGDS, and SOX9-shRNA-containing lentiviral vectors were
obtained from the National RNAi Core Facility (Academia Sinica, Tai-
wan) and prepared in accordance with standard protocols. Cells
were infected with lentivirus (multiplicity of infection 5) in medium
containing polybrene (8 μg/mL). Three PTGDS shRNAs targeted to nu-
cleotides 540 to 560 (5′-CAGGGCTGAGTTAAAGGAGAA-3′), 590 to
611 (5′-CACAGAGGATACCATTGTCTT-3′), and 625 to 645 (5′-GATA
AGTGCATGACGGAACAA-3′) were synthesized based on Genbank ac-
cession NM_000954. Three SOX9 shRNAs targeted to nucleotides
1234 to 1253 (5′-ACCTTCGATGTCAACGAGTTT-3′), 1761 to 1781
(5′-GATAAGTGCATGACGGAACAA-3′), and 3680 to 3700 (5′-GCATCC
TTCAATTTCTGTATA-3′) were synthesized based on Genbank acces-
sion NM_000346.
3. Results
3.1. RIG1 and PTGDS were highly expressed in normal testis tissue
The RIG1 and PTGDS expression proﬁles in normal and cancer
tissue were analyzed by in silico data mining, using mRNA expres-
sion data from the GeneNote database (http://bioinfo2.weizmann.
ac.il/cgi-bin/genenote/home_page.pl). This analysis showed that
both RIG1 and PTGDS mRNA were highly expressed in normal
lymph node, spinal cord, lung, liver, testis, and placenta tissues.
Lower expression of RIG1 and PTGDS mRNA was observed in can-
cer tissues derived from the above tissue types (Fig. 1A). The ex-
pression levels of RIG1 and PTGDS were conﬁrmed in 13 normal
tissues using conventional RT-PCR. High expression levels of both
RIG1 and PTGDS cDNA, at 150 bp and 201 bp in length, respective-
ly, were ampliﬁed from cDNA derived from normal tissues of brain
and testis after 35 cycles of ampliﬁcation (Fig. 1B). Higher expres-
sion of RIG1 and PTGDS mRNA in brain and testis tissues was
conﬁrmed using quantitative real-time PCR analysis (Fig. 1C).
Although the gene expressions of RIG1 and PTGDS in silico data
are somewhat different from our results in different tissues, high
expressions of both RIG1 and PTGDS in testis tissue are consistent
with that in in silico data. Human testis cell samples from normal
cells, testicular embryonal carcinoma, and testicular seminoma
were used to clarify the expression of RIG1 and PTGDS in order
to conﬁrm that RIG1 and PTGDS are expressed in these testis sam-
ples (Fig. 1D). Quantitative real-time PCR analysis showed that the
gene expression of RIG1 and PTGDS in the normal cells was higher
than that in the carcinoma (RIG1 pb0.001, PTGDS p=0.002) or
seminoma (RIG1 pb0.001, PTGDS p=0.003) testis cancer cells
(Fig. 1E). The result seems to implicate RIG1 and PTGDS in the
regulation of cell function in testis cells and possibly in the
inhibiting of testicular carcinogenesis.
3.2. RIG1 suppresses migration and invasion of NT2/D1 testis cells
The members of the HREV107 protein family exhibit growth-
suppressive activities in various cancer lines [6,26,27]. Therefore,
Fig. 1. RIG1 and PTGDS were highly expressed in testis normal tissues. The analysis of mRNA expression of RIG1 and PTGDS in different normal and cancerous tissues was modiﬁed
from the GeneNote database (A). cDNA derived from total RNA of normal human tissues was prepared. Expression of RIG1 and PTGDS was analyzed by conventional RT-PCR (B) or
quantitative real-time PCR (C). Expression of actin served as the control. Cycles of PCR are indicated in parentheses. Total testis RNA derived from four normal, three carcinoma, or
three seminoma were purchased from Origene technologies and cDNA were prepared. The expression of RIG1 and PTGDS in normal and cancer tissue of testis was assessed by con-
ventional RT-PCR (D) or quantitative real-time PCR (E). Expression values are normalized on the mean of actin gene expression.
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and death of NT2/D1 testis cancer cells. Overexpression of RIG1
or a transmembrane-spanning C-terminus truncated with RIG1
(RIG1ΔC) in NT2/D1 cells did not appear to inﬂuence cell death
or viability (Fig. 2, A and B). However, we observed a dramatic de-
crease in migrated and invaded cells by 44% and 59%, respectively,
in RIG1-expressing NT2/D1 cells (Fig. 2, C and D). Truncation of
RIG1 at the C-terminus (RIG1ΔC) resulted in complete loss of the
activity that suppresses cell migration and invasion in NT2/D1
cells.
3.3. RIG1 associates and co-localizes with PTGDS
In a previous study, we carried out a yeast two-hybrid analysis to
identify the interaction of the NC domain of RIG1 and PTGDS. Their
interaction was further conﬁrmed in NT2/D1 cells. We performed
co-immunoprecipitation, using anti-myc antibody against the myc
epitope of RIG1 fusion proteins and using lysates of PTGDS-Flag
transfected NT2/D1 cells. The PTGDS protein was demonstrated on
immunoblots from RIG1 but not from RIG1ΔC co-transfected immu-
noprecipitates, indicating the presence of PTGDS in the RIG1pull-down protein complexes prepared in vitro (Fig. 3A). Similarly,
RIG1 but not RIG1ΔC was present in the PTGDS immunoprecipitates
(Fig. 3B). It is surprising that RIG1ΔC containing NC domain did not
interact with PTGDS, which suggests that RIG1 may interact with
PTGDS in a constricted space. Truncation of the C-terminus of
RIG1 led to homogenous distribution and complete loss of bind-
ing activity. To further validate the endogenous interaction of
RIG1 and PTGDS, we performed co-immunoprecipitation, using
anti-RIG1 or anti-PTGDS antibodies in NT2/D1 cell lysates. Our re-
sult revealed that endogenous RIG1 can interact with PTGDS
(Supplemental Fig. 1).
To further verify the co-localization of RIG1 and PTGDS in vivo, we
co-transfected NT2/D1 cells with pEGFP-PTGDS and various
pDsRed-RIG1 expression vectors. Eighteen hours after transfection,
EGFP-PTGDS was localized in the perinuclear region. DsRed-RIG1 fu-
sion protein was primarily distributed in the discrete compartment
of the perinuclear region, where DsRed-RIG1would co-localize
(yellow) with EGFP-tagged PTGDS protein (Fig. 3C). DsRed-RIGΔC
was distributed homogenously within the cell and showed no
co-localization with EGFP-PTGDS, which localized predominantly in
the perinuclear region.
Fig. 2. RIG1 suppresses cell migration and invasion. NT2/D1 cells plated in triplicate in 24-well plates were transfected with 500 ng of myc-tagged RIG1 expression vectors for
3 days. Cell death and cell viability were detected by LDH release (A) and WST-1 assay (B), respectively. Representative results of three independent experiments are shown
and expressed as average and standard error of the means after normalization with the control group at 24 h. Serum-starved cells in triplicate were added in upper polycarbonate
membrane inserts in 24-well plates. Lower wells contained 700 μL of DMEMwith 20% FBS, which was used as chemoattractant. Migratory cells were stained after 24 h of incubation
(C). Invasive ability was measured with the Matrigel invasion assay after 72 h of incubation. Representative results of three independent experiments are shown (D). Student's
t-test: ** Pb0.01.
2231C.-C. Wu et al. / Biochimica et Biophysica Acta 1823 (2012) 2227–22363.4. RIG1 enhances PTGDS activity
To examine the effect of RIG1 on PTGDS activity, NT2/D1 cells
were co-transfected with the PTGDS expression vector and the
RIG1, RIG1ΔC, or control vector. Twenty-four hours after transfection,
expression of PGD2 was induced speciﬁcally by activation of PTGDS as
determined by EIA detection. Expression of PTGDS increased PGD2
levels in NT2/D1 cells by 39%. In NT2/D1 cells co-transfected with
PTGDS and RIG1, PGD2 levels increased by 193% (Fig. 4A). Expressing
only RIG1 in NT2/D1 cells enhanced PGD2 expression by 117%.
Expression levels of cAMP and SOX9, which were stimulated by
the PGD2 produced by PTGDS, were also examined in RIG1-
expressing cells. PGD2 elevated intracellular cAMP levels in
NT2/D1 cells (Fig. 4B). cAMP production was increased by 43% in
PTGDS-expressing cells and reached a 69% when RIG1 was
co-expressed. Expressing RIG1 only in NT2/D1 cells did enhance
the cAMP levels by 52%. Cells treated with Br-cAMP, a stable
cAMP analogue, showed expression change of SOX9 by 3.8-fold
when compared to control cells (Fig. 4C). Also, RIG1 enhanced
the expression of SOX9 in NT2/D1 cells by 4.7-fold. The activation
of SOX9 was involved in both the nuclear translocation and
PGD2-induced, cAMP-activated, PKA-mediated phosphorylation of
SOX9 [25]. In order to determine the activated status of SOX9 ex-
pression up-regulated in RIG1-expressing cells, we next analyzed
whether RIG1 affects SOX9 subcellular distribution, using cell
fractionation results in NT2/D1 cells. Also, both SOX9 and phos-
phorylated SOX9 were up-regulated and were detected exclusively
in the nucleus fraction of cells that were treated with Br-cAMP or
expressed RIG1 (Fig. 4D). RIG1ΔC eliminated the interaction of
PTGDS and the ability to induce PGD2, cAMP production andSOX9 activation in NT2/D1 cells (Fig. 4, A–C). These results re-
vealed that PGD2 expression was up-regulated in RIG1-expressed
cells. Furthermore, the expression of PGD2 induced the production
of cAMP and the activation of SOX9.
Because RIG1 can enhance PTGDS activity, the effect of PTGDS on
RIG1-mediated RAS suppression in cervical cells was also examined.
The EGF-stimulated Ras-GTP level was suppressed in cells transfected
with the RIG1 expression vector. RIG1 was observed to enhance
PTGDS activity in NT2/D1 cells. In contrast, PTGDSwas observed to in-
hibit RIG1-mediated RAS suppression in a dose-dependent manner
(Supplemental Fig. 2) in HtTA cells. The result suggests that PTGDS
might interact with RIG1 and that this subsequently blocked the com-
plex formation of RAS and RIG1.
3.5. Silencing of PTGDS and SOX9 expression decreases RIG1-mediated
suppression of cell migration and invasion
Previous studies have conﬁrmed that the HREV107 protein family
acts as a phospholipase A, which can release free fatty acids and
lysophospholipid from phosphatidylcholine [20,21]. Also, phospholi-
pase A activity is required for PTGDS-mediated PGD2 production in
mast cells [28,29]. We used a known PLA1/2 inhibitor, AACOCF3, to
determine the role of phospholipase activity in the effect of RIG1 on
the PGD2 pathway. Inhibition of PLA1/2 by AACOCF3 had no
effect on RIG1-induced PTGDS activity, cell migration, or invasion
(Supplemental Fig. 3). This result suggests that phospholipase activity
is not required for the induction of RIG1-mediated PTGDS activity.
To determine whether the PGD2 pathway contributes to RIG1-
mediated suppression of cancer cell migration/invasion, we examined
the effects of PTGDS- and SOX9-silencing on the production of PGD2
Fig. 3. RIG1 associates and co-localizes with PTGDS. NT2/D1 cells plated in a 10-cm dish were transfected with 3 μg PTGDS-Flag along with the RIG1-myc or RIG1ΔC-myc expression
vector or with the control vector for 24 h. The cell lysates were prepared, and the interaction between RIG1 and PTGDS was analyzed by immunoprecipitation followed byWestern
blot analysis. Immunoprecipitates were resolved by SDS-PAGE and immunoblotted using the anti-Flag antibody (A) or anti-myc antibody (B). The levels of total PTGDS, RIG1, and
actin in the cytosolic extracts were detected by Western blotting. NT2/D1 cells were cotransfected with EGFP-PTGDS and either DsRED-RIG1 or DsRED-RIG1ΔC expression vectors
for 18 h. Cells were ﬁxed, stained with DAPI, and analyzed with a laser scanning confocal microscope (C). Scale bar: 10 μm.
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D1 cells were transducted with three different shRNAs to inhibit
PTGDS or SOX9 expression. As shown in Fig. 5, A and B, expression
of PTGDS in NT2/D1 cells was suppressed when transducted with
the PTGDS-1 or PTGDS-3 shRNAs. SOX9 expression was suppressed
in each of three SOX9 shRNA-transfected NT2/D1 cells. The expres-
sion of neither PTGDS nor SOX9 was affected when cells were
transducted with LacZ shRNA. Our results showed that PGD2 and
cAMP expressions were markedly decreased (suppression ranging
from 44.7 to 58% and from 44.1 to 49.3%, respectively) in PTGDS
shRNA-silencing cells (Fig. 5C). Furthermore, expression level of
RIG1-stimulated SOX9 was 51.5 to 74.1% lower than that of
LacZ-silencing cells (Fig. 5D). Although SOX9 shRNAs did not affect
RIG1-mediated PGD2 or cAMP production, both PTGDS- and
SOX9-silencing shRNAs alleviated the suppression of RIG1-mediated
cell migration and invasion (Fig. 5, E and F). Thus, our results suggest
that RIG1 could suppress cell migration and invasion in testis cancer
cells by affecting PGD2 signaling pathways.3.6. RIG1-induced suppression of cell migration and invasion is accomplished
by the PGD2 signaling pathway via stimulation of DP1 receptor
The biological effects of PGD2 are transduced by D prostanoid re-
ceptor (DP) 1 and DP2. To determine the mechanisms by which RIG1
affects PGD2 inhibition of cell migration and invasion, we examined
intracellular cAMP levels after treating cells with DP antagonist. In-
creased PGD2 expression was observed in RIG1-expressing cells.
This would not be affected by cells treated with DP1 antagonist
BWA868C or DP2 antagonist BAY-u3405. However, RIG1 can signiﬁ-
cantly elevate intracellular cAMP levels and SOX9 expression that
would be blocked by BWA868C but not by BAY-u3405 (Fig. 6, A
and B). These results suggest that DP1 receptor participates in the in-
hibition processes of SOX9 expression. Cell migration and invasion
were suppressed, respectively, in PGD2-treated (89.2% and 89.7%)
and RIG1-expressing (63.3% and 52.8%) NT2/D1 cells (Fig. 6, C and
D). Our results also showed that only BWA868C prevented the sup-
pression of RIG1-mediated cell migration and invasion (Fig. 6, C and
Fig. 4. RIG1 increases PGD2 and cAMP levels and enhances PGD2-mediated SOX9 subcellular localization. NT2/D1 cells plated in triplicate in 6-well plates were transfected with
1 μg PTGDS-Flag along with RIG1-myc or RIG1ΔC-myc expression vector for 24 h. Alternatively, the cells were treated with 1 mM Br-cAMP for 18 h or 500 ng/mL PGD2 for 1 h.
Cell lysates were prepared, and levels of PGD2 (A) or cAMP (B) were measured using an enzyme immunoassay. Representative results from triplicate samples were expressed
as mean±SD. *, Pb0.05; **, Pb0.01; ***, Pb0.001. Cells were transfected with RIG1 or RIG1ΔC expression vector for 24 h or treated with 1 mM Br-cAMP for 18 h. Expression of
SOX9 was determined by Western blot analysis using anti-SOX9 antibody (C). Cells were transfected with RIG1 or RIG1ΔC expression vector for 24 h or treated with 1 mM
Br-cAMP for 18 h. Nuclear and cytosolic fractions were prepared, and subcellular distribution of nuclear and cytosolic SOX9 and phosphorylated SOX9 was determined by Western
blot analysis (D).
2233C.-C. Wu et al. / Biochimica et Biophysica Acta 1823 (2012) 2227–2236D). A similar alleviation of PGD2-suppressed migration and invasion
was also observed in cells treated with BWA868C (data not shown).
4. Discussion
Our results indicate that ectopic RIG1 in testis cancer cells may
serve as a PTGDS activator that regulates the PGD2 pathway and
cancer migration and invasion. We found that expression of RIG1
in NT2/D1 cells suppresses cell migration and invasion and en-
hances PTGDS-induced PGD2 production. We suspect that expres-
sion of RIG1 in NT2/D1 cells might directly or indirectly affect the
DP1 receptor and downstream signaling pathway to further ele-
vate cAMP levels and SOX9 activation. We also observed reversion
of RIG1-mediated migration and invasion suppression in PTGDS-
and SOX9-silenced NT2/D1 cells after transduction with shPTGDS
and shSOX9. A similar result was observed in cells treated with
DP1 antagonist BWA868C. Emerging evidence has suggested that
RIG1 speciﬁcally regulates cancer migration/invasion, through the
PGD2 signaling pathway (Fig. 7).
RIG1 belongs to the HREV107 type II tumor suppressor family,
which regulates cellular apoptosis, differentiation, and growth sup-
pression. Previous studies have focused on the effects of the HREV107
protein family in suppressing RAS-mediated transformation in cancercells [6,8,10,11,19,27]. Although the anti-RAS effect induced by
HREV107 protein family has been veriﬁed, the direct interaction of RAS
and RIG1 in cancer cells has not been observed [11]. The literature
scarcely mentions the relationship between RAS and the differentiation
of testis tissue even though PTGDS can suppress RIG1-mediated RAS
suppression. In contrast, the PGD2 pathway is well-known in testis
differentiation in themouse model [25,30,31]. PGD2-induced regulation
of cell differentiation and suppression of migration and invasion in
cancer cells have also been reported [32–34]. PGD2 is known to
stimulate cAMP production to inhibit TGF-β1-induced epithelial-to-
mesenchymal transition by up-regulating E-cadherin in Madin–Darby
canine kidney cells [32]. Whether the expression of E-cadherin is regu-
lated by SOX9 needs further investigation. PGD2 and cAMP participate
in multiple signaling pathways, which may explain why the reversion
of RIG1-mediated suppression of migration and invasion in RIG1-
expressing cells was slightly higher using PTGDS shRNAs than with
cells transfected with SOX9 shRNA (migration p-value=0.004, invasion
p-value=0.032) (Fig. 5, E and F). Previous studies have indicated that
combined treatmentwith PGD2 and retinoic acid substantially decreases
tumor growth in human ex vivo andmouse in vivomodels ofmelanoma
[35]. Interestingly, RIG1 is retinoid acid-inducible, which suggests that
RIG1 might be inclusive in retinoid acid-mediated testicular tumor sup-
pression [36,37].
Fig. 5. PTGDS and SOX9 shRNAs alleviate the RIG1-mediated suppression of migration and invasion. NT2/D1 cells were transducted with the indicated shRNAs for 72 h, cell lysates
were prepared, and the expression of PTGDS (A) or SOX9 (B) was determined using anti-PTGDS or anti-SOX9 antibodies. Cells were transducted with indicated shRNA for 72 h and
then transfected with RIG1 expression vector for 24 h. The levels of PGD2 and cAMP were determined using an enzyme immunoassay (C), and expression of SOX9 was determined
by Western blot analysis using anti-SOX9 antibody (D). Representative results from triplicate samples were expressed as means±SD. Migration (E) and invasiveness (F) were de-
termined in cells transduced with indicated shRNA. Representative results of three independent experiments are shown. Student's t-test: *, Pb0.05; **, Pb0.01; ***, Pb0.001 versus
control; #, Pb0.01 versus RIG1-expressing cell that transducted with shLacZ.
2234 C.-C. Wu et al. / Biochimica et Biophysica Acta 1823 (2012) 2227–2236There is little discussion in the literature concerning the relation-
ship between cell migration/invasion and the PGD2-SOX9 signal
pathway in testis cells. Contrary to our study, SOX9 might be an
oncoprotein and its expression has been linked to urothelial carci-
noma cell-lines invasion [38]. Other research results have men-
tioned the role of SOX9 in cell differentiation. SOX9 has been
shown to directly bind CREB as a novel synergism with the
protein kinase A pathway in BMP-2-induced osteochondrogenic dif-
ferentiation [39]. Also, PGD2 synergizes cAMP and induces SOX9 ac-
tivation and subsequent Sertoli cell differentiation [25,40]. The
results show that the combination of SOX9 and a different signal
pathway will alter cell function.
According to our results, the interaction of the HREV107 protein
family with PTGDS might play an important role in testis cell devel-
opment or differentiation when RIG1 and PTGDS co-express and
co-interact in the testis cell (Fig. 7). Our hypothesis is supportedby the following: (1) high mouse H-rev107 (RIG1 homology pro-
tein) expression levels in differentiated testicular tissues in mice
suggests that H-rev107 expression is correlated with testicular de-
velopment [15]; (2) expression of PTGDS has been detected in the
cellular lineage that gives rise to Sertoli cells [41], and the Sertoli
cells appear to express PGD2 synthase only during stages VI–VIII
of the spermatogenic cycle, immediately after spermiation [42];
(3) PGD2 can induce SOX9 nuclear translocation and subsequent
Sertoli cell differentiation [25]; and (4) we identiﬁed the RIG1-
binding protein using the NC domain of RIG1, and the domain is
highly homologous with another HREV107 protein family. By com-
paring amino acid sequences of RIG1 with mouse H-rev107, we
found that 39% of their amino acids are identical. This suggests
that mouse H-rev107 might interact with PTGDS due to its similar-
ity to RIG1 (as RIG1 is expressed in the human species only).
Whether the mechanism of differentiation induced by mouse
Fig. 6. PGD2 DP1 antagonist alleviates the RIG1-mediated suppression of migration and invasion. NT2/D1 cells were transfected with RIG1 and incubated with 10 μM BWA868C or
BAY-u3405 for 24 h. Cell lysates were prepared, and the expression of PGD2, cAMP, or SOX9 was determined by enzyme immunoassay (A) and immunoblotting (B). NT2/D1 cell
lysates were treated with 500 ng/mL PGD2 or transfected with RIG1 expression vector and incubated with 10 μM BWA868C or BAY-u3405 for 24 h. The cells were added in trip-
licate in upper polycarbonate membrane inserts in 24-well plates. Lower wells contained 700 μL of DMEM with 20% FBS, which was used as chemoattractant. Migratory cells were
stained after 24 h of incubation (C). Invasiveness was measured with the Matrigel invasion assay after 72 h of incubation (D). BWA868C or BAY-u3405 was present during migra-
tion and invasion. Representative results of three independent experiments are shown. Student's t-test: **, Pb0.01; ***, Pb0.001.
Fig. 7. Proposed model of the RIG1/PTGDS pathway. This schematic representation depicts
that PTGDS is enhancedbyRIG1 to increase PGD2, triggers the PGD2DP1/cAMP/SOX9 signal-
ing pathways, and then suppresses cellmigration and invasion or induces cell differentiation.
2235C.-C. Wu et al. / Biochimica et Biophysica Acta 1823 (2012) 2227–2236H-rev107 is similar to that of PGD2, which is mediated through the
regulation of SOX9 gene expression, as proposed by Malki et al. [25],
needs further investigation.
Aside from RAS suppression, previous studies seem to indicate
that RIG1-mediated cell differentiation and cancer suppression re-
sult in a modulate expression or activity such as HER2, PI3K/AKT,
mTOR, or tissue transglutaminase I [12,13,43]. These observations
suggest that RIG1 has multiple functions in various tissues and
that the different signal pathways involved in RIG1-mediated cell
differentiation/cellular apoptosis might be due to the difference in
speciﬁc binding protein. Regardless of speciﬁc downstream signal-
ing, most results from previous studies demonstrate that C-
terminus is required for HREV107 protein family-mediated cell dif-
ferentiation and apoptosis [10,13,26,27,44]. Truncation of RIG1 at
the C-terminus (RIGΔC) results in complete loss of the activity
that binds PTGDS and then activates the PGD2 signal pathway, al-
though RIGΔC has the NC domain. In addition, different truncated
RIG1 variants are distributed differently within a cell [26]. It
2236 C.-C. Wu et al. / Biochimica et Biophysica Acta 1823 (2012) 2227–2236becomes difﬁcult to perform domain mapping of the RIG1–PTGDS
complex in vivo under these circumstances.
Our ﬁndings provide insights into the molecular mechanism by
which RIG1 enhances PTGDS, thus regulating cancer invasion and
metastasis. The ﬁnding that RIG1 forms a complex with PTGDS to
mediate the PGD2 signaling pathway and suppress cancer cell inva-
sion may offer new targets for treatments to prevent cancer
metastasis.
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